Antigenics Inc.
News and overview for Antigenics Inc.
Genzyme slides on outlook; Antigenics tanks - MarketWatch
MarketWatch | 33 days 4 hours 40 minutes ago
Shares of Genzyme /quotes/comstock/15*!genz/quotes/nls/genz (GENZ 53.66, -1.19, -2.17%) were down over 2% at $53.60.
European CHMP Formally Adopts Negative Opinion on Oncophage [Press Release]
Business Wire | 3 days 5 hours 50 minutes ago
Antigenics Inc. (NASDAQ: AGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has formally adopted a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) as a treatment in earlier-stage, localized renal cell carcinoma (kidney cancer). A negative vote of the CHMP indicating this opinion was verbally conveyed to Antigenics and announced in a press release issu...
Antigenics withdraws Oncophage application in Europe following negative recommendation
Sun (Baltimore), The | 3 days 2 hours 32 minutes ago
Biotechnology company Antigenics Inc. said Friday it will not seek approval for a potential kidney cancer treatment after a European advisory committee recommended against approving the drug candidate.
Antigenics Provides Details On GlaxoSmithKline s Pivotal Malaria Vaccine Trial With QS-21 Adjuvant [Press Release]
Business Wire | 19 days 7 hours 15 minutes ago
Antigenics, Inc. (NASDAQ: AGEN) today indicated that GlaxoSmithKline’s (GSK) Phase III malaria vaccine clinical trial, containing Antigenics’ QS-21 Stimulon® adjuvant, has enrolled more than 5,000 children to date and is expected to involve up to 16,000 children. The pivotal efficacy study of RTS,S, the world’s most clinically advanced malaria vaccine, is ongoing in seven African countries.
Antigenics Reports Third Quarter 2009 Financial Results [Press Release]
Business Wire | 25 days 8 hours 15 minutes ago
Antigenics Inc. (NASDAQ: AGEN) reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted. For the nine months ended September 30, 2009, the company incurred a net loss attributable to ...
Antigenics withdraws Oncophage application in Europe following negative recommendation -- South Florida Sun-Sentinel.com
Sun-Sentinel (Fort Lauderdale, Fla.) | 3 days 3 hours 15 minutes ago
LEXINGTON, Mass. (AP) — Biotechnology company Antigenics Inc. said Friday it will not seek approval for a potential kidney cancer treatment after a European advisory committee recommended against approving the drug candidate.
EMEA informs Antigenics on a negative opinion for Oncophage MAA
News-Medical.Net | 33 days 5 hours 47 minutes ago
Antigenics Inc. (NASDAQ: AGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMEA), has verbally informed the Company at an oral meeting to anticipate a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) in early-stage, localized renal cell carcinoma (kidney cancer).
Antigenics sees negative EU review for Oncophage
Forbes | 33 days 3 hours 49 minutes ago
LEXINGTON, Mass. -- Antigenics Inc. said Wednesday it has been told a European Union regulatory committee will recommend against approval for Antigenics' cancer drug Oncophage, and the news sent its shares plunging.
UPDATE 1-Antigenics cancer vaccine gets negative EU panel vote
Reuters | 3 days 2 hours 57 minutes ago
Nov 20 (Reuters) - Antigenics Inc (AGEN.O) said an advisory committee of European health regulators formally rejected its application to market a potential cancer vaccine, Oncophage, and that it would withdraw the filing.
Antigenics pulls European Oncophage application
Charlotte Observer (N.C.), The | 3 days 2 hours 34 minutes ago
LEXINGTON, Mass. Biotechnology company Antigenics Inc.
GSK's malaria vaccine trial containing Antigenics' Stimulon adjuvant enrolls more than 5,000 children
News-Medical.Net | 19 days 4 hours 52 minutes ago
Antigenics, Inc. (NASDAQ: AGEN) today indicated that GlaxoSmithKlines (GSK) Phase III malaria vaccine clinical trial, containing Antigenics QS-21 Stimulon® adjuvant, has enrolled more than 5,000 children to date and is expected to involve up to 16,000 children. The pivotal efficacy study of RTS,S, the worlds most clinically advanced malaria vaccine, is ongoing in seven African countries.
Antigenics buoyed by brain-cancer study
American City Business Journals | 28 days 4 hours 46 minutes ago
Drug developer Antigenics Inc. said researchers at the University of California, San Francisco, reported positive results stemming from a study using its cancer therapy Oncophage to treat brain-cancer patients.
UPDATE 1-Antigenics to get negative EU opinion on cancer vaccine
Reuters | 33 days 5 hours 36 minutes ago
* Shares fall as much as 43 pct Oct 21 (Reuters) - Drugmaker Antigenics Inc (AGEN.O) said it was verbally informed by the European health regulator that the company would get a negative opinion on the marketing application of its experimental cancer vaccine Oncophage.
UPDATE 2-Antigenics says EU may not OK kidney cancer vaccine
Forbes | 33 days 1 hour 29 minutes ago
BANGALORE, Oct 21 (Reuters) - Drug developer Antigenics Inc said European health regulators are likely to turn down its application to market a kidney cancer vaccine, sending its shares down 43 percent.
STOCKS NEWS US-Antigenics plummets, EU may not OK vaccine
Forbes | 33 days 58 minutes ago
Stocks on the move Real-time Equity news U.S. stock market report 1246 ET 21Oct2009-Antigenics plummets, EU may not OK vaccine ------------------------------------------------------------------------------
Sign up for ANA SmartBrief
Company Overview
| Company: | Antigenics Inc. |
|---|---|
| Industry: | Biopharmaceuticals & Biotherapeutics |
| Website: | http://www.antigenics.com |
Cancer and other diseases had better beware -- Antigenics is packing heat. The firm develops heat shock proteins, which are related to the immune system's response to disease. Its patient-specific vaccines work on the theory that each person's cancer has a unique signature and are derived from the tumor after it has been removed. Lead drug candidate Oncophage is the first personalized cancer vaccine to receive FDA fast track status (a designation that expedites the approval of treatments for serious diseases); it has this designation for kidney and skin cancers. Another cancer vaccine candidate in the firm's pipeline targets genital herpes.
Key Numbers
| Sales in U.S. Dollars (mil.) | 2.7 (2008) |
|---|---|
| One-year % Growth in Sales | -52.3 (2008) |
| Net Income in U.S. Dollars (mil.) | -28.7 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 80 (2008) |
| One-year % Growth in Number of Employees | -20.0 (2008) |
| Fiscal Year-End | December |